DR REDDYS LABORATORIES LTD (RDY) Form 6-K — Aug 17, 2026
Dr. Reddy's Laboratories disclosed that the USFDA completed a GMP inspection of its FTO-3 formulations manufacturing facility in Bachupally, Hyderabad, conducted from August 6 to August 14, 2026. At the close of the inspection, the agency issued a Form 483 with four observations, which the company says it will address within the stipulated timeline. No warning letter, import alert, or production restriction was disclosed.
Key figures
- Inspection Window
- August 6, 2026 to August 14, 2026
- Inspection Facility
- FTO-3 formulations manufacturing facility, Bachupally, Hyderabad
- Fda Form483 Observations
- 4
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.